We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+4.63%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$104M
AUM Growth
-$25.8M
Cap. Flow
-$29.3M
Cap. Flow %
-28.32%
Top 10 Hldgs %
55.77%
Holding
61
New
9
Increased
3
Reduced
31
Closed
18

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$22.6M
2
IBB icon
iShares Biotechnology ETF
IBB
+$4.76M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$3.22M
4
GSK icon
GSK
GSK
+$2.11M
5
IQV icon
IQVIA
IQV
+$1.44M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$3.11M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$2.63M
3
EPZM
Epizyme, Inc
EPZM
+$2.3M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$2.14M
5
PCRX icon
Pacira BioSciences
PCRX
+$1.86M

Sector Composition

Rank Sector Weight
1 Healthcare 62.03%
2 Real Estate 0.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
iShares Russell 2000 ETF
IWM
$79.1B
$23M 22.21%
+200,000
New +$22.6M
BMY icon
2
Bristol-Myers Squibb
BMY
$129B
$5.27M 5.09%
71,703
-5,397
-7% -$381K
MRK icon
3
Merck
MRK
$322B
$4.82M 4.66%
87,718
-6,602
-7% -$351K
IBB icon
4
iShares Biotechnology ETF
IBB
$9.45B
$4.55M 4.39%
+53,043
New +$4.76M
PFE icon
5
Pfizer
PFE
$143B
$3.95M 3.82%
118,364
+2,424
+2% +$77.4K
ALKS icon
6
Alkermes
ALKS
$8.11B
$3.58M 3.46%
82,858
-19,419
-19% -$801K
AZN icon
7
AstraZeneca
AZN
$269B
$3.28M 3.17%
54,282
+14,732
+37% +$856K
XBI icon
8
State Street SPDR S&P Biotech ETF
XBI
$10B
$3.18M 3.07%
+58,857
New +$3.22M
MDVN
9
DELISTED
MEDIVATION, INC.
MDVN
$3.11M 3%
51,561
-54,797
-52% -$3.11M
SGEN
10
DELISTED
Seagen Inc. Common Stock
SGEN
$2.99M 2.89%
74,093
-35,829
-33% -$1.36M
AMGN icon
11
Amgen
AMGN
$209B
$2.83M 2.74%
18,619
-8,565
-32% -$1.33M
INCY icon
12
Incyte
INCY
$25.8B
$2.82M 2.72%
35,237
-16,440
-32% -$1.28M
ILMN icon
13
Illumina
ILMN
$29.5B
$2.63M 2.54%
19,266
-3,071
-14% -$436K
MTD icon
14
Mettler-Toledo International
MTD
$28.1B
$2.62M 2.53%
7,188
-2,312
-24% -$845K
VRTX icon
15
Vertex Pharmaceuticals
VRTX
$123B
$2.6M 2.51%
30,248
-10,889
-26% -$941K
NKTR icon
16
Nektar Therapeutics
NKTR
$2.39B
$2.54M 2.45%
11,902
-7,309
-38% -$1.63M
REGN icon
17
Regeneron Pharmaceuticals
REGN
$72.9B
$2.53M 2.44%
7,233
-1,696
-19% -$653K
ALNY icon
18
Alnylam Pharmaceuticals
ALNY
$38.3B
$2.42M 2.34%
43,684
-33,909
-44% -$2.14M
QGENF
19
DELISTED
QIAGEN NV
QGENF
$2.31M 2.23%
105,751
-29,249
-22% -$638K
CELG
20
DELISTED
Celgene Corp
CELG
$2.26M 2.18%
22,932
-16,664
-42% -$1.72M
BMRN icon
21
BioMarin Pharmaceuticals
BMRN
$11.9B
$2.25M 2.17%
28,915
-19,345
-40% -$1.64M
BIIB icon
22
Biogen
BIIB
$30.9B
$2.19M 2.11%
9,042
-2,083
-19% -$549K
GSK icon
23
GSK
GSK
$107B
$2.17M 2.09%
+40,000
New +$2.11M
ALXN
24
DELISTED
Alexion Pharmaceuticals
ALXN
$2.02M 1.95%
17,301
-8,104
-32% -$1.15M
AGIO icon
25
Agios Pharmaceuticals
AGIO
$2.08B
$1.81M 1.75%
43,295
-7,705
-15% -$381K
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return

Opus Point Partners Management's Q2 2016 Portfolio in Review

As of Q2 2016, Opus Point Partners Management held 61 positions worth $104M, down 20% from $129M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Opus Point Partners Management withdrew a net $29.3M in Q2 2016, closing 18 positions and reducing 31 holdings. Its most notable exit was ProShares Ultra NASDAQ Biotechnology, an estimated $2.63M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 70% a quarter earlier, followed by Real Estate.

Against the trend, Opus Point Partners Management opened a new position in iShares Russell 2000 ETF worth $23M.

  • Opus Point Partners Management's largest Q2 2016 buy was iShares Russell 2000 ETF: 200,000 shares worth $23M.
  • Opus Point Partners Management added most to AstraZeneca in Q2 2016, an estimated $856K increase.
  • Opus Point Partners Management's biggest Q2 2016 reduction was MEDIVATION, INC., cutting an estimated $3.11M.
  • Opus Point Partners Management fully exited ProShares Ultra NASDAQ Biotechnology in Q2 2016, selling an estimated $2.63M.
  • Opus Point Partners Management's ten largest holdings make up 56% of its $104M portfolio in Q2 2016.
  • Opus Point Partners Management opened 9 new positions and closed 18 in Q2 2016.
  • Opus Point Partners Management's portfolio value fell 20% quarter-over-quarter to $104M.

Based on Opus Point Partners Management's 13F filing for Q2 2016, filed 15 Aug 2016.